Quarterly report · Q1
2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥501.8bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥450.3bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥30.8bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥11.0bn | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.2bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥25.9bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.6bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥32.6bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥11.3bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.00T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.47T | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.55T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.44T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.46T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.23T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.16T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥971.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥151.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥116.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥39.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥65.3bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.4bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥34.7bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥8.6bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 38.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥20.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥15.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | −¥158m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥12.3bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥238.6bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥238.2bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥379m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥32.7bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥31.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥726m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥1.7bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥122.2bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥121.5bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥645m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥12.2bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥105.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥105.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥67m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥16.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥22.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥6.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥16.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | −¥265m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥11.5bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥225.4bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥225.1bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥300m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥20.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥991m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥1.4bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥108.6bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥108.0bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥609m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥9.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥93.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥93.4bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥107m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥16.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 779
| Item | Context | Value | Unit |
|---|---|---|---|
| Finance costs IFRS | Prior1YTDDuration | 1363000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 8485000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 20063000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember | 238173000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 121510000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember | 105503000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember | 31929000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4647000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 501762000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember | 379000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 645000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember | 67000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember | 726000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 15345000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -17162000000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration | - | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember | 238553000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 122155000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember | 105569000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember | 32655000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 19992000000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | -17162000000 | JPY |
| Revenue IFRS | CurrentYTDDuration | 501762000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000AlcoholicBeveragesReportableSegmentMember | 18431000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 12245000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000PharmaceuticalsReportableSegmentMember | 16516000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E00395-000HealthScienceReportableSegmentMember | -1652000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -158000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -12326000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 33055000000 | JPY |
| Other operating income IFRS | CurrentYTDDuration | 3231000000 | JPY |
| Other operating expenses IFRS | CurrentYTDDuration | 5457000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 6667000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 2341000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 9017000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 44172000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第186期第1四半期(自 2024年1月1日 至 2024年3月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)キリンホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Kirin Holdings Company, Limited | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長COO 南 方 健 志 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中野区中野四丁目10番2号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03(6837)7015 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)財務戦略部長 松 尾 英 史 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中野区中野四丁目10番2号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03(6837)7015 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |